AtriCure (ATRC) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company Following 2Q Beat
July 28, 2017 8:07 AM EDTNeedham & Company raised its price target on AtriCure Inc. (NASDAQ: ATRC) to $26.00 (from $25.00) while maintaining a Buy rating following the company's 2Q. Revenue was $45.2M vs. consensus of $44.2M, EBITDA was ($0.4M) vs. consensus of ($1.9M), and EPS was ($0.21) vs. consensus of ($0.26).
For... More
